For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Medinox, Inc.

Calculating rank

USPTO Granted Patents = 25

% Expired Patents = 24.0

EPO Patents = 1

Forward Citations = 500

Loading Chart...

Loading Chart...

7 inventors (with patents filed for the assignee):

Ching-San Lai (24 out of 30 patents)

Vassil P Vassilev (9 out of 9 patents)

Tingmin Wang (8 out of 10 patents)

4. Long-Shiuh Chen (2 out of 2 patents)

5. Wei-Cheng Liaw (1 out of 4 patents)

6. Jean-Frédérick Salazar (1 out of 1 patent)

7. Van-Duc Le (1 out of 1 patent)

Core Competencies:

Pharmacologically Active Agents

Nitric Oxide Scavengers

Dithiocarbamates

Therapeutic Methods

Sickle Cell Anemia

Conjugates

Disulfide Derivatives

Hydroxamate Derivatives

Inflammation Treatment

Iron Level Reduction

Cyanide Level Reduction

Antibody Preparation

25 patents: Sort by Forward Citations

1. RE41151 - Protected forms of pharmacologically active agents and uses thereof (2010-02-22),

2. 6710086 - Protected forms of pharmacologically active agents and uses therefor (2004-03-23),

3. 6649591 - Polydithicarbamate-containing non-targeting marcomolecules and the use thereof for therapeutic and diagnostic applications (2003-11-18),

4. 6620813 - Hydroxamate derivatives of non-steroidal anti-inflammatory drugs (2003-09-16),

5. 6596770 - Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor (2003-07-22),

6. 6596733 - Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide (2003-07-22),

7. 6589991 - Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor (2003-07-08),

8. 6555563 - Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation (2003-04-29),

9. 6429223 - Modified forms of pharmacologically active agents and uses therefor (2002-08-06),

10. 6407135 - Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor (2002-06-18),

11. 6355666 - Protected forms of pharmacologically active agents and uses therefor (2002-03-12),

12. 6355661 - Methods for treatment of sickle cell anemia (2002-03-12),

13. 6316502 - Therapeutic methods employing disulfide derivatives of dithiocarbonates and compositions useful therefor (2001-11-13),

14. 6306842 - Protected forms of a combination of pharmacologically active agents and uses therefor (2001-10-23),

15. 6274627 - Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor (2001-08-14),

Company Overview

Medinox, Inc. is a biotechnology company based in San Diego, California, specializing in the development of innovative medical devices and therapeutic solutions. The organization focuses on advancing healthcare through cutting-edge research in areas such as drug delivery systems and regenerative medicine. By leveraging its expertise in biocompatible materials and advanced engineering, Medinox aims to enhance patient outcomes and improve the quality of life for individuals with various medical conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

25 Patents

#243 in San Diego, CA

#3,165 in California

#13,388 in US

#25,766 in the World

San Diego, CA, United States of America

Medinox, Inc.

Forward Citations = 500

7 inventors:

Ching-San Lai (24 out of 30 patents)

Vassil P Vassilev (9 out of 9 patents)

Tingmin Wang (8 out of 10 patents)

4. Long-Shiuh Chen (2 out of 2 patents)

5. Wei-Cheng Liaw (1 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Medinox, Inc.. Retrieved from https://idiyas.com/company/medinox

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…